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Abstract
Background: Increased platelet activation in sickle cell disease (SCD) contributes to a state of hypercoagulability and confers
a risk of thromboembolic complications. The role for post-transcriptional regulation of the platelet transcriptome by
microRNAs (miRNAs) in SCD has not been previously explored. This is the first study to determine whether platelets from
SCD exhibit an altered miRNA expression profile.
Methods and Findings: We analyzed the expression of miRNAs isolated from platelets from a primary cohort (SCD= 19,
controls = 10) and a validation cohort (SCD= 7, controls = 7) by hybridizing to the Agilent miRNA microarrays. A dramatic
difference in miRNA expression profiles between patients and controls was noted in both cohorts separately. A total of 40
differentially expressed platelet miRNAs were identified as common in both cohorts (p-value 0.05, fold change.2) with 24
miRNAs downregulated. Interestingly, 14 of the 24 downregulated miRNAs were members of three families - miR-329, miR-
376 and miR-154 - which localized to the epigenetically regulated, maternally imprinted chromosome 14q32 region. We
validated the downregulated miRNAs, miR-376a and miR-409-3p, and an upregulated miR-1225-3p using qRT-PCR. Over-
expression of the miR-1225-3p in the Meg01 cells was followed by mRNA expression profiling to identify mRNA targets. This
resulted in significant transcriptional repression of 1605 transcripts. A combinatorial approach using Meg01 mRNA
expression profiles following miR-1225-3p overexpression, a computational prediction analysis of miRNA target sequences
and a previously published set of differentially expressed platelet transcripts from SCD patients, identified three novel
platelet mRNA targets: PBXIP1, PLAGL2 and PHF20L1.
Conclusions: We have identified significant differences in functionally active platelet miRNAs in patients with SCD as
compared to controls. These data provide an important inventory of differentially expressed miRNAs in SCD patients and an
experimental framework for future studies of miRNAs as regulators of biological pathways in platelets.
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Introduction
Sickle cell disease (SCD) is characterized by chronic hemolytic
anemia as a result of a single point mutation in the beta-globin
gene (Val–Glu) leading to the formation of a sickle hemoglobin
(HbS). This HbS molecule has a propensity to polymerize when
deoxygenated, rendering the sickle red blood cells (SS RBCs) less
deformable with propensity to cause vaso-occlusion in the
microvessels. Central in SCD pathogenesis is acute and chronic
endothelial injury and inflammation leading to vasculopathy and
activation of the coagulation system. Among the many compo-
nents of the hemostatic system, increased platelet activation plays
a catalytic role in SCD vasculopathy [1,2,3]. Markers of platelet
activation such as a) increased expression of activation dependent
antigens, P-selectin and glycoprotein IIbIIIa, on circulating
platelets [3,4,5], b) increased plasma concentrations of platelet
factor 4 [4], beta-thromboglobulin [4], thrombospondin-1 (TSP-1)
[6,7] and soluble CD40 ligand [8] and c) increased numbers of
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e60932
circulating platelet microparticles [3] have been detected in
patients with SCD in steady state and are amplified during acute
vaso-occlusive crisis [3]. Activated platelets contribute to vaso-
occlusive crises and intimal damage by increased adhesion of SS
RBCs to the endothelium [9] via secretion of fibrinogen, von
Willebrand factor (vWF) [1] and TSP-1 [7,10]. In addition,
activated platelets play a key role in promoting intimal hyperplasia
by secreting vasoactive and mitogenic substances for the fibroblasts
and smooth muscle cells such as platelet-derived growth factor
(PDGF) and transforming growth factor-beta (TGF-b) [11,12].
Platelets synthesize an elaborate set of proteins in a timely and
signal-dependent manner but little is known as to how their
transcriptome is modulated. Gene expression studies of platelets
were traditionally limited by the low abundance of platelet RNA
which stipulates processing of large volumes of blood (,50 ml) to
obtain 1 to 4 mg of RNA. The development of microarray
technology paired with RNA amplification techniques has allowed
for high-throughput transcript profiling of platelets in multiple
disease states including coronary heart disease [13], essential
thrombocythemia [14] and systemic lupus erythematosus [15]. We
have successfully analyzed the amplified platelet transcriptome in
SCD patients from single donors using these techniques [16] and
we identified ,100 differentially expressed genes in SCD as
compared to controls with increased expression of genes involved
in arginine metabolism and redox hemostasis. This study indicates
that platelets from SCD patients have distinct gene expression
patterns possibly involved in SCD-specific platelet biology.
One of the significant advances in molecular biology in the past
decade has been the recognition of microRNAs (miRNAs) which
are small noncoding RNAs of approximately 18–25 nucleotides in
length. They regulate target mRNAs by repressing translation or
inducing nucleolytic cleavage through their binding to their 39
untranslated regions (39 UTR) [17,18]. More than 800 miRNAs
have been discovered in humans, although the function of many
remains unknown. There is evidence that at least one third of the
human genome is regulated by miRNAs, and perhaps more than
60% of the human protein-coding genes [18]. Recent data suggest
an important regulatory role of miRNAs in hematopoietic
differentiation such as megakaryocytopoiesis [19], erythropoiesis
[20,21], and in hematological malignancies [22,23]. There are
very few published studies to date documenting presence of
miRNAs in platelets from pooled apheresis samples [24] and from
healthy donors [25,26,27,28,29]. The identity and expression
levels of miRNAs in platelets of patients with SCD have not been
examined to date.
This is the first comprehensive study undertaken to elucidate the
signature miRNAs of platelets from SCD and healthy controls
using microarrays in two distinct patient cohorts. Our findings
confirm the previous studies showing that anucleate platelets
contain diverse and abundant miRNAs. Importantly, we have
identified SCD-specific alterations in miRNAs that relate to the
SCD platelet transcriptome profile as described in our previously
published study [16]. We have further identified three novel target
mRNAs as a result of upregulation of miRNA-1225-3p in SCD
patients. These findings provide an experimental framework for
the study of dysregulation of platelet miRNA and the pathogenesis
of SCD.
Materials and Methods
Ethics Statement
The study was approved by the Institutional Review Boards of
University of Pittsburgh Medical Center (UPMC) and National
Heart, Lung, and Blood Institute (NHLBI) and written informed
consent was obtained from all participants in accordance with the
Declaration of Helsinki.
Subjects
For the miRNA array study, a cohort of 19 patients with SCD
(hemoglobin SS) and 10 controls were selected from the outpatient
clinic at NHLBI. To validate the findings of the microarray data,
a validation cohort consisting of 7 SCD patients and 7 controls
were selected from UPMC. The controls did not have any
hemoglobinopathy and individuals on anticoagulant or anti-
platelet medications were excluded. We also excluded history of
coronary artery disease or its equivalents, atrial fibrillation or
infectious disease which could influence platelet reactivity.
Smoking history was not available in all our subjects and thus its
effect on platelet miRNA expression profile in this study
population could not be assessed.
Platelet Preparation
Twenty milliliters of peripheral blood was collected from
patients and controls in CPT tubes and samples were processed
within 15 minutes of blood collection. Samples were centrifuged at
1506g for 10 minutes, and platelet-rich plasma was carefully
aspirated and re-centrifuged at 1506g for 5 minutes to remove
remaining red and white cells. Platelet-rich plasma was centrifuged
again at 15006g for 10 minutes to pellet the platelets. The cell
pellet was then washed twice with erythrocyte lysis buffer to
remove traces of contaminating red blood cells and once with
phosphate-buffered saline (PBS).
Purity of the preparation was checked by flow cytometric
measurement of cells expressing glycoprotein IIb/IIIa antigen. In
brief, 100 ml of cell preparation was mixed with 100 ml of PBS
containing 2% fetal calf serum (FCS). Samples were incubated on
ice in the dark for 15 minutes with either fluorescein isothiocya-
nate (FITC) labeled CD45 antibody to assess leukocyte contam-
ination or phycoerythrin (PE) labeled CD41a antibody for
platelets. Mouse anti-human IgG1k-PE and IgG1k-FITC were
used as isotype controls (Becton Dickinson, San Jose, Calif).
Following incubation, the cells were washed with PBS/FCS,
pelleted by centrifugation at 3006g for 5minutes and resuspended
in 0.5 ml PBS/FCS. Platelets were identified using BD FACS
caliber flow cytometer by their characteristic light scatter and the
platelet-specific antibody CD41a binding to glycoprotein IIb/IIIa.
At least 25,000 events were counted with fluorescence intensity
greater than a threshold set at 1% from the respective negative
control sample. In addition, cell count was used to determine
purity of the preparation and was checked in a Cell-Dyn Coulter
counter 3700 (Abbott Diagnostics, Abbott Park, Ill). For this the
platelet pellet was washed with PBS.
Cell Culture
MEG-01 cells (CRL-2021; American Type Culture Collection
[ATCC], Manassas, VA), were used for miRNA transfection
experiments. These were cultured in RPMI 1640 medium (ATCC)
supplemented with 10% fetal bovine serum and penicillin/
streptomycin in a humidified incubator under 5% CO2 at 37uC.
Transfection of MEG-01 Cells with miR-1225-3p
MEG-01 cells (16106 ) were transfected with either 200 nM of
pre-miRNA 1225-3p or negative control pre-miRTM miRNA ds-
oligo precursors (Ambion, Austin, TX) using AmaxaH Nucleo-
fector Kit C (Lonza) and NucleofectorII H Device (Amaxa Inc.
Walkersville, MD) as per manufacturer’s instructions. Cells were
incubated for 24 hours with the miRNA prior to RNA purification
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for gene expression analysis. Transfection efficiency was estimated
in parallel by co-transfection of a GFP-expressing plasmid
(pmaxGFPH Vector, Lonza) and flow cytometric analysis of
GFP-expression 24 hours post NucleofectionH. The pre-miRTM-
miRNA precursor molecules acting as negative control #1
(Ambion Inc., TX) have a random sequence and have no known
human mRNA target.
RNA Isolation
Platelets and MEG-01 cells were lysed in lysis buffer containing
phenol and guanidinium thiocyanate. Total RNA, including
miRNAs and mRNAs, was isolated using miRNeasy mini kit
(Qiagen, Valencia, CA) and RNAqueous miRNA isolation kit
(Ambion, Austin, Texas) at the UPMC and NHLBI sampling
locations, respectively. The concentration of the isolated RNA was
determined using Nanodrop ND-1000 spectrophotometer (Nano-
drop Technologies, Wilmington, Del). Quality and integrity of the
total RNA isolated were assessed using the RNA 6000 Pico kit
with the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA). The total RNA yield from 20 ml of peripheral blood
was in the range of 500–1000 ng.
Microarrays
MiRNA profiling was performed as previously described by us
[30], with an 8615 K Agilent human miRNA microarray
(Version 3.0, Agilent Technologies) containing 866 miRNAs
(Sanger miRbase release 9.1), with each miRNA having three or
four unique probes on the array. Labeling and hybridization of
100 ng of total RNA was performed according to the protocol
described by the manufacturer. Briefly, 100 ng of total RNA was
dephosphorylated using calf intestine alkaline phosphatase,
denatured with DMSO, and labeled with Cyanine 3 (Cy3) using
T4 RNA ligase at 16uC for 2 h. The labeled RNA was purified
using Micro Bio-spin 6 columns and hybridized onto the miRNA
microarrays at 55uC for 20 h.
Gene expression microarray was performed as previously
described by us [30]. Briefly, 100 ng of total RNA was labeled
using the One-Color, Agilent Low Input Quick Amp Labeling Kit
(Agilent Technologies) following the protocol described by the
manufacturer. Briefly, total RNA was used as a template for
double-stranded cDNA synthesis. The cDNA was used by T7
RNA polymerase as a template to generate Cy3-labeled cRNA
that was used for hybridization on Agilent Sure Print G3 Human
GE 8660 K Microarrays (Agilent Technologies) at 65uC for 17 h.
The arrays were washed with Gene Expression Wash Buffers 1
and 2 (Agilent Technologies) and scanned using the Agilent
Microarray Scanner (Agilent Technologies). The scanned images
were processed by Agilent’s Feature Extraction software version
9.5.3. All microarray data has been deposited in the Gene
Expression Omnibus (GEO) under accession number GSE41575.
Microarray Data Processing and Analysis
MiRNA microarray data were log base 2 transformed and
quantile normalized. Only those miRNAs with mean expression
values for each probe greater than 95% of the mean values of the
negative control probes under at least one condition, sickle cell
disease or control, were considered for further statistical analysis.
Gene expression microarray data were log 2-transformed and
cyclic loess normalized as previously described by us [30]. The
normalized data was expressed as the difference of log of g
Processed Signal (Agilent Feature Extraction) and log of geometric
mean of controls.
Transformed data from all the arrays were subjected to
a principal component analysis to detect outliers. Student’s
unpaired t-test was used to identify those miRNAs that were
differentially expressed (P,0.05 or ,0.1, fold-change.2
(FC.2)) between SCD and controls and disease subgroups
using Genespring software (www.agilent.com/chem/genespring)
and BRB-Array Tools v.4.1.0. Similar criteria were used to find
differentially expressed genes between miR-1225-3p and nega-
tive control miRNA (scrambled) transfected MEG-01 cells. The
false discovery rate (FDR) was controlled at 5% to correct for
multiple comparisons. Microarray data from a previously
published platelet gene expression study (NHLBI SCD study)
(Gladwin et al, unpublished data) [16] was also reanalyzed using
the above criteria. Data visualization and Clustering was
performed using Scoregene package as described [31], Tree-
View [32] and Genomica programs (http://genomica.
weizmann.ac.il/).
Multiple algorithms (Targetscan [33]- http://www.targetscan.
org, miRanda [34]- http://www.microrna.org and PicTar -
http://pictar.org) were then used to refine those miRNAs with
relatively platelet-specific targets for validation. To evaluate
whether a given pathway was overrepresented in the list of
differentially expressed miRNAs and genes, statistical softwares-
IngenuityH Systems (IPA, www.ingenuity.com ) and DAVID
Bioinformatics Resources 6.7 [35] were used. DAVID software
was also used to look for gene-enrichment associated with
a certain biological process (annotation term) from the
calculated Fisher Exact p-Value. An EASE score is calculated
using the p-values of the individual members of each Functional
Annotation Cluster [36]. Smaller p-values and higher scores for
a cluster of enriched terms signify more importance of the
group in the study. In our study we used a FDR of ,0.05 and
EASE score of .1.3 as cutoff.
We calculated the enrichment of SCD platelet genes among
the differentially expressed genes in the transfected MEG-01
cells by using a hypergeometric distribution test. For the above
calculation, we used the total number of genes in the Affymetrix
chip (N= 31,355, Affymetrix Human Genome U133 Plus 2.0)
and the total number of differentially expressed genes in SCD
platelets vs controls (n = 2039 with FDR 5% and n= 518 with
FC.2) from the NHLBI SCD study [16] against the
differentially expressed genes in the miR-1225-3p transfected
MEG-01 cells vs scrambled (x = 2642 with FDR 5% and
x= 1037 with FC.2) and the number of genes present in both
the lists. An illustration of all the analyses used in this study is
presented in Figure S1.
Prediction of microRNA Targets
For the target prediction of the selected miRNAs, we used
a novel algorithm, ComiR [37]. By design, ComiR predicts the
target genes of a set of miRNA genes by considering multiple
miRNA binding events on the same mRNA (in the 39UTR
region). ComiR improves the predictions of four popular motif
finders (Targetscan [33], mirSVR [38], PITA [39], miRanda [34])
by weighing their predictions by miRNA expression or by using
the Fermi-Dirac model as more accurate prediction of target site
occupancy. Then, it integrates the predictions obtained from these
four target prediction tools, using a support vector machine (SVM)
trained on Drosophila Ago1 immunoprecipitation data. Each gene
is assigned with a ComiR score, which is the class probability
estimate of the SVM for the gene to be a functional target of the
set of miRNAs. ComiR algorithm takes into account for the
miRNA abundance levels. Thus, for the same set of miRNAs,
different miRNA expression profiles produce different ComiR
scores.
Platelet miRNAs in Sickle Cell Disease
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Validation of microRNA and mRNA Data by Real-time
Quantitative Reverse Transcription-Polymerase Chain
Reaction (qRT-PCR)
To validate the miRNA array data, 10 ng of total RNA was
reverse transcribed using TaqMan microRNA Reverse Transcrip-
tion Kit (Applied Biosystems, Foster City, CA). Real-time PCR
(RT-PCR) was performed in triplicate per sample using TaqMan
miRNA assays and Taqman Universal PCR Master Mix (Applied
Biosystems). PCR reactions were set up to have 0.9 ng of cDNA
and were run in ABI 7900 HT real-time PCR system according to
the manufacturer’s instructions. The results were analyzed by the
comparative cycle threshold method (DDCt method) using
RNU43 amplification as endogenous control. Statistical signifi-
cance was determined by Student t test, setting P,0.05 as
threshold.
For mRNA qRT-PCR, total RNA was reverse transcribed to
cDNA using High-Capacity cDNA Reverse Transcription kit
(Applied Biosystems). RT-PCR was performed on 40 ng of cDNA
per reaction using TagMan Gene Expression Assays (Applied
Biosystems) (see below) and TaqMan Gene Expression Master
Mix (Applied Biosystems). The results were analyzed by the
comparative cycle threshold method (DDCt method) using BGUS
amplification as endogenous control. Statistical significance was
determined by Student t-test, setting P,0.05 as threshold.
TaqMan Assays: MT1X (Hs00745167_sH), IFI6
(Hs00242571_m1), PTPN6 (Hs00169359_m1), FCER1G
(Hs00175408_m1), RAP2A (Hs00702699_s1), BCR
(Hs01036532_m1), FRMD3 (Hs00604157_m1), IGF1R
(Hs00609566_m1), PTGER3 (Hs00168755_m1), PBXIP1
(Hs00933587_m1), PLAGL2 (Hs01122758_m1) and PHF20L1
(Hs01036397_m1), GUSB (Hs99999908_m1).
Results
Patient Characteristics
The clinical characteristics of the miRNA array cohort (NHLBI)
and the validation cohort (UPMC) are shown in Table 1.
Individuals in the NHLBI cohort consisted of 19 SCD patients
and 10 controls. The median age of the patients was 51 years
whereas that of controls was 43 years. There was an almost equal
distribution of females in both the groups (,70%). Doppler-
estimated increases in pulmonary artery systolic pressure, i.e.
elevated tricuspid regurgitant velocity (TRV), was present in 68%
of patients and 53% were on Hydroxyurea (HU) at the time of
study enrollment. The UPMC cohort consisted of 7 SCD patients
and 7 control subjects with a similar median age of ,38 years.
Women were overrepresented in the control group (57%) as
compared to patients (29%). Similar to the NHLBI cohort, there
were 71% patients with elevated TRV and 57% on HU. The two
independent cohorts of SCD patients from UPMC and NHLBI
had similar clinical features and no significant differences in the
laboratory parameters. Similar numbers of patients in both
cohorts were on hemodialysis, chronic transfusion and on
Aspirin/Plavix. Subgroup analysis to study the impact of these
factors on platelet expression did not yield any significant results.
MicroRNAs are Differentially Expressed in Platelets in
Sickle Cell Disease
Our protocol was optimized to obtain a highly pure platelet
population with minimum leukocyte contamination. For each
sample, flow cytometric assessment for platelet purity revealed
a highly enriched platelet population with more than 95% cells
positive for CD41a, with less than 0.2% CD45+ leukocytes and
non-CD41a, non-CD45 cellular debris (Figure 1A). Cell counts
on the platelet preparations demonstrated that the white blood cell
count ranged from 0–0.3610‘3/ml and platelets ranged from 1–
2610‘6/ml. This amounted to roughly 0.03% leukocytes or less in
the platelet preparations. Platelet gene expression profiling studies
of platelet rich plasma have been considered specific with
contaminating leukocytes of only 0.4% [25,27,40,41]. In addition,
we performed qRT-PCR in a few SCD and control platelet
samples to assess the expression of residual leukocyte-specific
message (CD45/PTPRC). We did not find any significant
difference in the expression level of CD45 between SCD and
control samples (Figure S3). This suggests that any residual
leukocyte contamination is present in all the samples in equal
degrees and can be treated as ubiquitous background that won’t
affect the profiles of the differentially expressed platelet miRNAs.
Table 1. Characteristics of Study Participants.*
NHLBI Cohort Median (Range) UPMC Cohort Median (Range) Overall Median (Range)
Characteristic SS (N=19)
Control
(N=10) SS (N=7)
Control
(N=7) SS (N=26)
Control
(N=17)
Age, y 51 (23–79) 43 (28–61) 38 (22–65) 37 (32–62) 49 (22–79) 40 (28–62)
Women, N (%) 14 (74) 7 (70) 2 (29) 4 (57) 16 (62) 11 (65)
HbSS, % 100 100 100
Pulmonary Hypertension, N (%) 13 (68) 5 (71) 18 (69)
Hydroxyurea, N (%) 10 (53) 4 (57) 14 (54)
Hemoglobin, g/dL 9.3 (6.2–13.2) 7.8 (6.1–10.3) 8.9 (6.1–13.2)
Platelet count,61023/mL 325 (92–943) 215 (102–442) 322 (92–943)
White blood cell count,61023/mL 6.0 (2.3–12.5) 10.4 (5.8–14.4) 6.6 (2.3–14.4)
Reticulocyte count,61023/mL 0.13 (0.04–0.46) 0.15 (0.01–0.49) 0.14 (0.01–0.49)
Fetal hemoglobin, % 9.9 (1.4–33.8) 2.9 (1.6–9.8) 8.4 (1.4–33.8)
Lactate dehydrogenase, U/L 291 (192–566) 347 (212–904) 305 (192–904)
Total bilirubin, mg/dL 1.5 (0.4–7.1) 2.0 (0.6–9.2) 1.7 (0.4–9.2)
*Age and Laboratory values indicate median (range).
doi:10.1371/journal.pone.0060932.t001
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Following RNA isolation and quality control using the Bioanaly-
zer, RNA samples with RIN value.7 were selected for further
microarray analysis (Figure 1B).
We compared the expression profiles of platelet human
miRNAs in both cohorts using the Agilent miRNA platform.
Stringent statistical filters of p-value of ,0.05 and FC.2 were
applied and the differentially expressed miRNAs between SCD
patients and controls were determined separately for the UPMC
and NHLBI cohorts. Our final differentially expressed list included
only common miRNAs identified in both cohorts, increasing the
selection stringency on our results. The larger NHLBI cohort
revealed 259 differentially expressed miRNAs passing our
statistical filters and the UPMC cohort identified 67 differentially
expressed miRNAs between SCD patients and controls. Forty
miRNAs were identified with significantly different levels in
platelets from SCD patients in both cohorts (Figure 1C). The
pattern of platelet miRNA expression is presented as a heatmap
using Scoregene which classifies the samples based on their
similarity (Figure 1D). Out of these 40 differentially expressed
miRNAs 16 were upregulated and 24 were downregulated in
SCD, consistently in both cohorts (Figure S2). The 20 most
significant differentially expressed miRNAs are listed in Table 2
in rank order of their expression level.
Computational Prediction of microRNA Targets with
ComiR
As an initial evaluation of these 40 differentially expressed
miRNAs, a bioinformatics-based data mining approach was used.
Our newly developed algorithm, ComiR [37], was used in this
analysis. Based on the miRNA expression profiles of the 40
differentially expressed miRNAs in the 43 subject samples the
ComiR likelihood score was calculated for each mRNA in each of
Figure 1. MiRNAs in platelets of SCD patients are differentially expressed. (A) Characterization of purified platelet preparation by flow
cytometry. (B) Bioanalyzer assessment of RNA samples from purified platelet preps showing good quality with RIN of 7.8. (C) Venn diagram
comparing differentially expressed miRNAs from two independent study cohorts. Comparison of 259 differentially expressed miRNAs from NHLBI
samples and 67 differentially expressed miRNAs from UPMC samples. In total, there are 40 miRNAs overlapping between the two cohorts. (D) The
heatmap depicts the 40 statistically significant (p-value,0.05, FC.2) differentially expressed miRNAs between SCD and controls that were common
between the two cohorts. Columns represent individual samples and each represents a miRNA. Upregulated miRNAs expression levels are shown in
progressively brighter shades of yellow, depending on the fold difference. Downregulated miRNAs are shown in progressively brighter shades of
purple. No difference is represented as grey. The names of the miRNAs are displayed to the right of the heatmap.
doi:10.1371/journal.pone.0060932.g001
Platelet miRNAs in Sickle Cell Disease
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e60932
the 43 samples. This score corresponds to the likelihood that the
mRNA expression is affected by the set of the 40 miRNAs
expressed at the sample associated miRNA abundance levels.
Then for each sample, a rank-order list of all mRNAs was created
based on the ComiR probability that their expression was affected
by the set of 40 miRNAs. To compare the rank of each mRNA
obtained from the SCD samples with that from the controls, we
performed a non-parametric Wilcoxon rank-sum test since the
population was not normally distributed and further applied FDR
of 5% for multiple comparisons correction. In order to select the
genes differentially predicted as target of the miRNAs expressed in
the two groups of samples, we chose those associated with a p-
value lower than 0.05 and which were also included in the top
10% predicted targets by ComiR in at least one of the two groups
of samples. The second filter was introduced to remove all the
genes with a significantly different rank in the two groups that
were not predicted as targets in any of the two groups. In this way,
we ended up with a list of 2309 genes. To determine whether the
ComiR generated list of 2309 target genes was reflecting gene
expression changes in SCD platelets, we compared it against the
list of differentially expressed genes from the NHLBI SCD study
(N= 518, FDR 5% and FC 2).We found 89 genes present in both
datasets which was more than expected by chance as determined
by hypergeometric distribution test (p-value 3.39497E214). Our
results suggest that ComiR provides a meaningful set of putative
targets that may be regulated by the 40 differentially expressed
miRNAs in platelets (Table S1).
Downregulated microRNAs from miR-329, miR-376 and
miR-154 Families in Platelets from Sickle Cell Disease Map
to the Maternally Imprinted 14q32.31 Locus
Amongst the 24 significantly downregulated miRNAs in SCD
platelets, 14 were found to be members of three families - miR-
329, miR-376 and miR-154 (Table 3). These miRNAs are
transcribed from the genes located at the 14q32.31 locus in the
human genome and map within a ,40 kb interval. Since the
majority (,60%) of the downregulated miRNAs that were
identified in SCD platelets belong to these families, we speculated
that these miRNAs and their targets may have an important role
in platelet physiology and SCD. Using Targetscan we identified
a total of 3583 conserved targets of all these 14 miRNAs. A
Functional Annotation Clustering of these genes using DAVID
Bioinformatics Resources 6.7 revealed that a significant number of
them are involved in the regulation of transcription, regulation of
cellular biosynthetic processes, cell morphogenesis and motility
(Table 4). We used KEGG charts from DAVID to explore the
distribution of these target genes among various biological
pathways and observed that all three miRNA families are
associated with signaling pathways such as Wnt signaling, TGF-
b signaling and adherens junction. Table 5 shows the KEGG
pathways that are highly enriched among all the miRNAs of the 3
miRNA families in our study, after using a FDR of 5% and EASE
score of .1.3 as cutoff.
Computational Evaluation of Differentially Expressed
microRNAs and Validation of Microarray Data
For the purpose of validating the microarray results, the
expression levels of several miRNAs were validated by qRT-PCR.
Limited by the quantity of RNA per sample we had to restrict
ourselves to choosing miR-376a of the miR-376 family, miR-409-
3p of the miR-154 family and miR-1225-3p of the most
upregulated miRNAs. These three miRNAs were selected based
on the following criteria 1) miRNA target databases (TargetScan,
Table 2. Twenty most differentially expressed (A) up- and (B)
down-regulated microRNAs (P,0.05, fold change.2)
between sickle cell disease (N = 26) and controls (N = 17)
ranked according to p-value (low to high).
(A) microRNA P value
Fold
Change Chromosome
miR-638 6.561026 15.9 19p13.2
miR-940 3.261025 14.9 16p13.3
miR-636 6.561025 6.4 17q25.1
miR-1238 1.161024 10.9 19
miR-1225-3p 1.161024 10.3 16p13.3
miR-1207-5p 1.161024 13.5 8
miR-33b* 1.161024 7 17p11.2
miR-1228 1.361024 12 12
miR-630 1.661024 24.2 15q24.1
miR-191* 2.261024 10.3 3p21.31
(B) microRNA P value Fold
change
Chromosome
miR-376a 6.561026 11.7 14q32.31
miR-381 6.561026 6.8 14q32.31
miR-409-3p 6.561026 6.5 14q32.31
miR-377 6.561026 6.5 14q32.31
miR-376c 1.661025 12.1 14q32.31
miR-495 1.861025 4.5 14q32.31
miR-376b 2.361025 4.5 14q32.31
miR-181c* 2.361025 3.9 19p13.13
miR-487b 3.261025 6.3 14q32.31
miR-337-5p 3.261025 4.6 14q32.2
doi:10.1371/journal.pone.0060932.t002
Table 3. Three distinct microRNA families among the
differentially expressed microRNAs.
miR Family microRNAs Regulation
Fold
Change p-value
hsa-miR-154 miR-381 down 6.8 6.49E206
miR-409-3p down 6.5 6.49E206
miR-377 down 6.5 6.49E206
miR-487b down 6.3 3.17E205
miR-323-3p down 2.7 3.17E205
miR-410 down 4.8 1.08E204
miR-409-5p down 2.9 1.26E204
miR-154* down 2.8 1.38E204
hsa-miR-329 miR-495 down 4.5 1.78E205
miR-329 down 2.4 6.34E204
miR-543 down 2.8 0.002
hsa-miR-376 miR-376a down 11.7 6.49E206
miR-376c down 12.1 1.62E205
miR-376b down 4.5 2.26E205
doi:10.1371/journal.pone.0060932.t003
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miRanda, and PicTar) predicted targets to these miRNAs which
were relevant to platelet biology. Gene ontology analysis revealed
that predicted targets of these 3 miRNAs were enriched for
regulation of transcription, transcription factor activity and
regulation of RNA metabolic process. 2) ingenuity pathway
analysis of the predicted targets revealed top canonical pathways
(as shown in Figure 2) that have been previously identified in
relation to megakaryocyte/platelet signaling such as beta-adren-
ergic signaling, Protein Kinase A signaling, ERK/MAPK
signaling, insulin receptor signaling and regulation of the actin
cytoskeleton (reviewed in [42,43,44,45,46]) (Figure 2). These
three miRNAs were also amongst the top twenty most differen-
tially expressed between SCD vs controls (Table 2). qRT-PCR
was performed in control and SCD samples of both cohorts and
confirmed that miR-376a and miR-409-3p were significantly
lower while miR-1225-3p was significantly higher in SCD as
compared to control samples (Figure 3).
MicroRNA-mRNA Regulation in Megakaryocytic Cell Line
To explore the functional role of miR-376a, 409-3p and miR-
1225-3p we used MEG-01 cell line in the place of human
megakaryocytes, which are difficult to obtain in large numbers. To
mimic the downregulated state of miR-376a and 409-3p in
platelets, we needed to transfect MEG-01 cells with inhibitors of
these miRNAs. Unfortunately, our initial PCR studies showed that
the baseline levels of miR-376a and miR-409-3p in MEG-01 cells
were already very low and often undetectable, making this
approach unfeasible. On the other hand, we could determine
the targets of miR-1225-3p by replicating the upregulated state in
SCD platelets by transfecting MEG-01 cells with a miR-1225-3p
mimic. Our hypothesis was that the overexpressed miRNAs would
cause mRNA degradation by directly binding to the 39UTR of its
targets and we would be able to identify these potential targets by
a negative correlation between the miRNA and the differentially
expressed mRNAs.
Successful transfection of MEG-01 cells with miR-1225-3p
mimic was confirmed by GFP detection and qRT-PCR
(P,0.05, transfected vs scrambled cells, n = 5 in each group)
(Figures 4A and 4B). A transfection efficiency of 70–75% was
achieved (Figure 4A). Microarray analysis of miR-1225-3p
transfected cells relative to the scrambled identified a total of
2642 genes differentially expressed at a FDR of 5%. Out of
these, a total of 1037 genes were upregulated and 1605 genes
were downregulated. Out of the 2642 genes, 1037 genes were
changed at a FC.2.
In order to decide whether this set of 2642 differentially
expressed genes from the transfected cells (FDR 5%) is enriched in
platelet-related genes, we interrogated our data against a defined
and general set of megakaryocytic and platelet genes. We explored
the IPA knowledge base for existing literature on genes annotated
under the terms ‘‘platelets’’ and ‘‘megakaryocytes’’. This generat-
ed a list of 426 genes (IPA list) which have been established to be
associated with biological functions in platelets and megakaryo-
cytes by a variety of studies. Amongst the 2642 genes a total of 75
genes overlapped with the genes from the IPA list. The calculated
probability of finding overrepresentation of platelet and megakar-
yocyte genes amongst the differentially expressed genes in
transfected cells was more than expected by chance as determined
by hypergeometric distribution test (p-value 5.28 E-08). This
comparison provides additional external validity that miR-1225-
3p is a strong candidate for regulating SCD-related platelet
biology. A list of these 75 genes with their biological functions
pertaining to platelets and megakaryocytes is presented in Table
S2.
To validate our microarray results, we tested 5 genes (MT1X,
RAP2A, IFI6, FCER1G and PTPN6) using qRT-PCR in each of
the miR-1225-3p and scrambled transfected samples. All of the 5
genes were downregulated in miR-1225-3p transfected cells
according to microarray data and were chosen based on fold
change values.3, p-value,0.05 and microarray signal intensity in
logarithmic scale were more than the median expression values of
all the genes in each sample/array. All five genes were confirmed
by qRT-PCR to be downregulated in miR-1225-3p transfected
cells (Figure 4C).
Identification of miR-1225-3p Megakaryocyte/Platelet-
Specific Target Genes
Although 75 out of 2642 differentially expressed genes are
known to be associated with platelet and megakaryocytic
biology, we wanted to identify novel genes that may play a role
Table 4. Functional annotation clustering of predicted target genes to the differentially expressed microRNAs belonging to three
distinct families located at chromosome 14q32.31.
Cluster EASE score Count (%) p-value Fold enrichment
Regulation of transcription 18.7 750 (21) 1.20E231 1.4
Positive regulation of RNA metabolic process 14.5 198 (5.5) 3.95E224 2.1
Negative regulation of gene expression 10.2 191 (5.3) 3.26E218 1.9
Cellular component morphogenesis 7.5 151 (4.2) 4.78E214 1.9
Cell migration 5.5 106 (3) 2.71E209 1.9
doi:10.1371/journal.pone.0060932.t004
Table 5. Top enriched pathways regulated by predicted
target genes of miRNAs belonging to 154, 329 and 376
families (FDR,0.05).
Pathway Count p-value
Fold
enrichment
Wnt signaling pathway 70 6.99E211 2.4
Pathways in cancer 116 2.82E209 1.8
Adherens junction 42 2.53E208 2.8
TGF-beta signaling pathway 40 4.66E205 2.4
Ubiquitin mediated proteolysis 53 2.34E204 2.0
Axon guidance 50 5.17E204 2.0
Tight junction 51 7.44E204 2.0
doi:10.1371/journal.pone.0060932.t005
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in SCD. For this purpose, we compared the genes that change
as a response to miR-1225-3p over-expression (x = 2642) to the
list of genes that are differentially expressed in SCD platelets
(n = 2039) (NHLBI SCD study). A total of 377 genes were
identified to be common between the two datasets after
applying a FDR of 5% and the probability of this finding to
occur not merely by chance was significant as calculated by the
hypergeometric distribution (p-value: 1.82E253)) (Figure 4D).
Out of the 377 differentially expressed genes, 37 show a FC.2
with a significant hypergeometric distribution as well (p-value:
6.4E206) (Figure 4D). Notably, 241 out of these 377 common
genes were downregulated in both miR-1225-3p transfected
MEG-01 and SCD platelets.
Using the list of genes obtained from ComiR prediction
algorithm we then sought to find the common genes between
the differentially expressed genes from miR-1225-3p transfected
MEG-01 cells and platelet samples from NHLBI SCD study
(Figure 4D). This resulted in a list of 57 genes using a filter of
5%FDR or 7 genes when an additional FC.2 filter was applied
(Table 6). Of these 7 genes, 3 were downregulated: PBXIP1,
PLAGL2 and IGF1R; and 4 were upregulated: BCR, PHF20L1,
PTGER3 and FRMD3. qRT-PCR confirmed that PBXIP1,
PLAGL2 and PHF20L1, were indeed differentially expressed
between transfected and scrambled cells (p-value,0.05)
(Figure 4E).
Comparison of Platelet microRNAs in Sickle Cell Disease
Based on Hydroxyurea Treatment and Tricuspid
Regurgitant Jet Velocity
We explored miRNA expression changes in subsets of SCD
patients based on HU treatment and presence of elevated
Doppler-estimated TRV (.2.5 m/sec). We performed a direct
comparison between these patient subsets to identify miRNAs
that are differentially expressed under each condition. We
identified 23 differentially expressed miRNAs between subjects
with and without increased TRV and 10 differentially expressed
miRNAs between the subjects on and off HU (Figures 5A and
5B). Surprisingly, but consistent with prior studies evaluating
global mRNA transcriptional profiles, the miRNA expression
profiles of patients on HU treatment was almost identical to
those not on HU [47]. Similarly, there are only subtle
Figure 2. Most significant predicted canonical pathways regulated by the target genes of the 3 miRNAs: 376a, 409-3p and 1225-3p
(p-value,0.01). Orange squares depict ratio which is the number of target genes associated with each pathway. The vertical line across the bars
represents the cut-off of the p-value.
doi:10.1371/journal.pone.0060932.g002
Figure 3. miR-376a and miR-409-3p are downregulated and
miR-1225-3p is upregulated in SCD platelets. qRT-PCR validation
of the microarray data. For each miRNA the blue bar represents controls
(n = 26) and the red bar represents SCD (n= 17). Y-axis shows fold
change of miRNAs in SCD samples with the expression level in controls
set to 1. Error Bars represent standard deviation.
doi:10.1371/journal.pone.0060932.g003
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Figure 4. miR-1225-3p regulates gene expression after transfection in MEG-01 cells. (A) Expression of the flourescent marker pmaxGFP
plasmid as determined by flow cytometry demonstrates 76% GFP expressing cells out of the viable cell population. (B) qRT-PCR assay confirms
overexpression of miR-1225-3p in MEG-01 cells (n = 5) vs scrambled (scr) (n = 5). (C) MT1X, PTPN6, IFI6, FCER1G and RAP2A are significantly
downregulated in MEG-01 transfected cells as validated by qRT-PCR. (D) Schematic representation of overlap in differentially expressed genes
between miR-1225-3p transfected MEG-01 cells and platelets from SCD patients. The numbers in the circles denote the differentially expressed genes
with the leftmost figure representing genes using a FDR of 5% and the rightmost figure after applying a stringent statistical filter of FC.2. Further
overlap with ComiR predicted target list of the 40 differentially expressed miRNAs resulted in a list of 7 genes potentially regulated by miR-1225-3p.
(E) Out of the 7 genes, PLAGL2 and PBXIP1 genes are significantly downregulated and PHF20L1 is significantly upregulated in miR-1225-3p
transfected cells vs scrambled. In the qRT-PCR figures (B, C and D), for each gene, the blue bar represents the cells transfected with scrambled RNA
(n = 5) and the red bar represents the miR-1225-3p transfected cells (n = 5). Y-axis shows fold change of miR-1225-3p in transfected cells with the
expression level in scrambled set to 1. Error bars are based on standard deviation. *denotes p-value,0.05.
doi:10.1371/journal.pone.0060932.g004
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differences in the platelet miRNA expression in patients with
and without high TRV.
Discussion
In this study, we identify a complex population of miRNAs in
circulating platelets in SCD as well as healthy individuals. Our
findings indicate that, platelets from SCD patients in two
independent cohorts had a dramatic and significant difference in
the expression pattern of 40 miRNAs, suggesting that
dysregulation of platelet miRNAs are implicated in the
pathogenesis of SCD. Stringent criteria were applied for the
purification of platelets from whole blood samples to ensure that
the observed miRNA profiles reflect changes occurring in
platelets and not in other blood cell types. In addition, we
found the expression of the 40 differentially expressed miRNAs
from our study to be undetectable in the miRNA profile of
PBMCs [6], thus providing an additional validation that
platelets have a distinct expression pattern. Although all the
differentially expressed miRNAs could play an important role in
SCD platelet biology, we chose to focus on miR-1225-3p which
was found to be upregulated in SCD platelets since it proved to
have a considerable number of predicted targets with potential
biologic role in platelets. We experimentally demonstrated that
dysregulation of miR-1225-3p in a cell culture model related to
platelets (Meg-01) had a dramatic impact on gene expression
profile and a significant number of the differentially expressed
genes (N= 377) were also changed in SCD platelets. Further-
more, nearly 18% of the differentially expressed genes from the
transfected cells have been experimentally proven to be relevant
to megakaryocyte and platelet function (IPA list), providing
additional validity for our findings and suggesting a key role for
miR-1225-3p in platelet biology and SCD. With the help of the
new prediction algorithm, ComiR, we reduced the list of the
differentially expressed genes (N= 377) down to 3 genes which
could be regulated directly or indirectly by the miR-1225-3p:
PBXIP1, PLAGL2 and PHF20L1.
The first target, PBXIP1 (pre-B-cell leukemia homeobox
interacting protein) regulates the transcription factor PBX1 by
blocking of the DNA binding PBX1-HOX nucleoprotein
complexes to their target regulatory elements. PBX proteins
have been shown to play an important role as transcription
factors for maintenance of hematopoiesis. An example of this
has been shown by overexpressing PBXIP1 in CD34+ stem cells
and erythroleukemia cell line (K562) causing induction of
erythroid colony formation. We have documented low PBXIP1
expression in SCD platelets (NHLBI SCD study) and down-
regulation in cells overexpressing miR-1225-3p. These findings
support a role of miR-1225-3p in regulating PBXIP1 which
could affect lineage commitment by promoting megakaryopoi-
esis and opposing erythropoiesis. Our second target, PLAGL2
(Pleomorphic adenoma gene-like 2),belongs to the PLAG family
of zinc-finger transcription factors [48]. PLAGL2 can act as
either an oncogene by activating thrombopoietin receptor (Mpl)
in hematopoietic progenitors or a tumor suppressor by initiating
cell cycle arrest and apoptosis via p73 activation. A significant
role of PLAGL2 is the regulation of TNF-a induced expression
of NCF2 gene and subsequent p67phox protein (cytosolic
component of NADPH oxidase) and superoxide production
[49]. NADPH oxidase is an important source of reactive oxygen
species (ROS) in human platelets and MEG-01 cells. Down-
regulation of PLAGL2 by miR-1225-3p overexpression in
MEG-01 cells and platelets (NHLBI SCD study), may link
miR-1225-3p to a compensatory role in limiting oxidative stress.
Similarly, analysis of the transcriptome of peripheral blood
mononuclear cells in SCD patients revealed significant up-
regulation of catalytic anti-oxidant enzyme systems [47]. The
third target, PHF20L1 (PHD finger protein 20-like 1), along
with its close ortholog PHF20 has been found to be a part of
the multisubunit human histone acetyltransferase complex,
involved in histone acetylation and post-translational modifica-
tion [50]. Knockout of PHF20 in mice has been seen to cause
defects in many hematopoietic tissues including bone marrow
and leads to aberrant thymocyte development [51]. To date
very little is known regarding the function of PHF20L1.
An intriguing finding from this study was that of down-
regulation of members of the miR-154, the miR-329 and miR-
376 family in SCD platelets. To our knowledge this is the first
time that miRNA families have been associated with a distinct
signature in platelets. These miRNA clusters are located at
14q32.31 locus in DLK1-DIO3 genomic region which includes
the maternally imprinted genes MEG3, MEG8 and antisense
RTL1 [52]. The expression of the maternally expressed as well
as repressed imprinted genes of this entire locus is defined by
the methylation status of their promoters [53]. Dysregulation of
this miRNA cluster has been well-described in relation to
hematologic malignancies, suggesting epigenetic regulation of
transcription factors affecting development and proliferation of
hematopoietic cells [54]. In the context of SCD, further studies
exploring the impact of methylation-acetylation changes of this
locus on the miRNA expression levels in cells of the
megakaryocyte lineage may provide an important clue to the
profound clinical heterogeneity observed in this monogenic
disorder. With this understanding, therapeutic epigenetic mod-
ifications of these miRNA clusters might become a novel
approach for controlling the dysregulation of homeostasis caused
by platelets in SCD. The miRNAs from the 14q32 region are
Table 6. List of novel putative target genes of miR-1225-3p from the differentially expressed genes (FDR,5%, FC.2).
Gene symbol Gene description Regulation Fold Change
BCR Breakpoint cluster region Up 9.5
PHF20L1 PHD finger protein 20-like 1 Up 2.5
PTGER3 Prostaglandin E receptor 3 (subtype EP3) Up 2.2
FRMD3 FERM domain containing 3 Up 2.2
PBXIP1 Pre-B-cell leukemia homeobox interacting protein 1 Down 5.1
PLAGL2 Pleomorphic adenoma gene-like 2 Down 2.7
IGF1R Insulin-like growth factor 1 receptor Down 2.2
doi:10.1371/journal.pone.0060932.t006
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involved in the regulation of important signaling pathways such
as Wnt and TGF-b [30] which have been implicated in platelet
function, activation and thrombosis [55,56]. Among the
predicted targets of miRNAs of the 14q32 region, we found
members of the adherens and tight junction pathways which
have not been previously reported in conjunction with this
locus. This novel finding might be relevant to SCD pathophys-
iology, as these pathways have been shown to be involved in
complex platelet-endothelial interactions and their deregulation
might play a role in endothelial dysfunction (reviewed in
[57,58]).
It can be assumed that since platelets are anucleate, the
biogenesis of the platelet miRNAs is from megakaryocytic
precursor cells, in which pri-miRNAs are encoded and converted
into pre-miRNAs before platelet formation. Nevertheless, platelets
possess a miRNA processing machinery, including Dicer, TRBP2
and Ago2 [25] which enables them to process pre-miRNA into
mature miRNA. Both of the above mechanisms contribute to
platelet miRNA profiles which suggests that the differential
expression of platelet miRNAs in patients with SCD could be
a result of (1) increased numbers of short-lived circulating young,
transcriptionally active platelets in SCD (megathrombocytes)
[59,60,61,62], (2) alterations in the megakaryocyte transcriptome,
and (3) alterations in the stability of the pre-formed miRNA in the
circulating platelets exposed to various physiological and patho-
logical conditions in SCD.
Undoubtedly there are certain limitations of our study. First,
there was a significant difference in the number of differentially
expressed miRNAs between the NHLBI and UPMC. This
possibly is a result of the phenotypic heterogeneity seen in the
SCD population from the two locations. Additionally, the ability
to detect larger set of differentially expressed miRNAs between
SCD and controls in UPMC cohort might be limited due to the
smaller sample size. The RNA preparation methodology was
also different between the samples derived from UPMC and
NHLBI. To address these concerns, we analyzed the miRNA
expression profile in the two cohorts independently and chose
only those miRNAs that were different in both cohorts. By
doing so, we specifically measure profiles relevant to SCD, as
opposed to the confounding factors such as age, gender and
coexisting medical conditions. Moreover, the list of differentially
expressed platelet miRNAs common to both cohorts, confirms
the robustness of this miRNA signature profile over a varied
SCD population. Second, we were limited by the amount of
blood drawn which limited the quantity of RNA obtained.
Therefore, we were able to validate only a few of the
differentially expressed miRNAs. Third, although we have
identified three novel targets, PBXIP1, PLAGL2 and PHF20L1
linked to the expression of miR-1225-3p, we do not provide
evidence of their role in alteration of platelet phenotype and
biology. This needs to be further explored in megakaryocytes
obtained by differentiating primary cell lines. Last, while we
have identified a distinctive downregulation of miRNAs
localized to the epigenetically regulated miRNA cluster on
chromosome 14q32, we were unable to perform a detailed
analysis of the regulation of this region in SCD. Analysis of the
epigenomic changes at this cluster in platelets cannot be carried
out because of lack of genomic DNA collected in these studies.
This is the first human platelet miRNA profiling study in SCD
platelets aiming to understand platelet gene regulation. SCD
patients are known to have activated platelets which contribute to
their thrombophilic state but the key molecular events and
pathways involved are still unknown. There is now evidence
regarding the role of miRNAs in hemostasis/thrombosis where
certain miRNAs associate with platelet reactivity [27,28] but very
little is known about the mechanistic role of miRNAs in SCD
platelets. A fundamental aspect of altered miRNA profile is to
affect a number of cellular targets but they could also have
important paracrine effects. For instance, microparticles shed from
platelets in the circulating blood raises a possibility of them serving
as a delivery vehicle for miRNAs to targeted vascular sites
[26,63,64,65]. Thus, the change in the miRNA expression profile
in SCD could not only modulate intrinsic platelet functions but
also influence peripheral blood and vascular cells. Our study
provides an important inventory of SCD associated miRNAs
Figure 5. miRNAs in platelets have a unique expression profile
in SCD patients based on Doppler-estimated TRV and HU
treatment. (A) The heatmap represents 23 statistically significant (p-
value,0.1, FC.2) differentially expressed miRNAs between subjects
with (N= 18) and without (N = 8) elevated TRV (.2.5 m/sec). (B) The
heatmap represents 10 statistically significant (p-value,0.1, FC.2)
differentially expressed miRNAs between the subjects on (N= 14) and
off HU (N= 12). Every row represents a gene and every column is
a patient. Upregulated miRNAs are shown in yellow color, down-
regulated miRNAs are shown in purple and no difference is grey. The
names of the miRNAs are displayed to the right of heatmap.
doi:10.1371/journal.pone.0060932.g005
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which could shed light on the regulatory pathways involved in the
pathogenesis of this complex disease and is another step towards
this long-sought goal.
Supporting Information
Figure S1 Workflow for the bioinformatics analyses used in the
study for predicting target genes of miR-1225-3p.
(TIF)
Figure S2 Two heatmaps for each of the cohorts-UPMC and
NHLBI, depicting the 40 statistically significant (p-value,0.05,
FC.2) differentially expressed miRNAs between SCD and
controls. The two cohorts display consistency in the directionality
of the differentially expressed miRNAs between controls and SCD
samples. Columns represent individual samples and each repre-
sents a miRNA. Upregulated miRNAs expression levels are shown
in progressively brighter shades of yellow, depending on the fold
difference. Downregulated miRNAs are shown in progressively
brighter shades of purple. No difference is represented as grey.
The names of the miRNAs are displayed to the right of the
heatmap.
(TIF)
Figure S3 Expression of leukocyte-specific CD45/PTPRC by
RT-PCR in SCD and control platelet samples did not reveal
a significant difference. For each miRNA the blue bar represents
controls and the red bar represents SCD. Y-axis shows fold change
of miRNAs in SCD samples with the expression level in controls
set to 1. Error Bars represent standard deviation.
(TIF)
Table S1 List of 89 common genes between ComiR generated
list of 2309 target genes and list of differentially expressed genes
from the NHLBI SCD study (N= 572, FDR 5% and FC 2).
(XLSX)
Table S2 List of differentially expressed genes (FDR,5%) in
transfected cells vs scrambled cells with functional annotations
pertaining to platelet and megakaryocytes (n = 75) based on IPA
knowledge base.
(DOCX)
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